



## OTSUKA MARYLAND RESEARCH INSTITUTE, INC.

2440 Research Boulevard  
Rockville, Maryland 20850  
Telephone 301.417.0900  
Facsimile 301.990.0036

Contact:           Debra Kaufmann                           Jeff McLaughlin  
                          240.683.3568                               202.955.6222 ext. 2530  
                          [debrak@otsuka.com](mailto:debrak@otsuka.com)                       [jmclaughlin@spectrumsience.com](mailto:jmclaughlin@spectrumsience.com)

### **MR. YOICHI NISHINAKAMURA JOINS OTSUKA MARYLAND RESEARCH INSTITUTE, INC. AS CHAIRMAN AND CHIEF EXECUTIVE OFFICER**

*New Chairman and CEO to Head Research and Development for  
Rockville, MD-Based Pharmaceutical Company*

ROCKVILLE, MD, September 2, 2003 – Otsuka Maryland Research Institute, Inc. (OMRI) has announced the appointment of Yoichi Nishinakamura as Chairman and CEO of the US clinical research and development subsidiary of Otsuka America, Inc., a US holding company established by Otsuka Pharmaceutical Co., Ltd. (OPC). Mr. Nishinakamura brings extensive experience in clinical research and development, pharmacovigilance, and pharmaceutical product marketing, gained over the course of his more than 30 years of employment with OPC in Japan. Mr. Nishinakamura also holds the office of President and COO of OMRI.

“We are very pleased that Mr. Nishinakamura has accepted the position of Chairman, CEO, President and COO of OMRI,” said Tatsuo Higuchi, President of OPC. “Because of his background, experience and long-time career with Otsuka, I am confident that he will prove to be highly effective in this important leadership role with OMRI.”

Mr. Nishinakamura’s positions with OPC have included responsibility for pharmaceutical research and development, pharmacovigilance, and product marketing. Positions he has held include Chairman of OPC’s Ethics Committee, Director General of the Otsuka Frankfurt Office of Clinical Research, Director of Headquarters of Overseas Business, Director of Otsuka’s Pharmacovigilance Department, Senior Operating Officer and Director of New Product Evaluation and Development, Senior Operating Officer and Leader of the Pharmaceutical Product Group, Pharmaceutical Marketing Division. He also held the position of Leader with Board Director Status of the Product Group, Pharmaceutical Marketing Division.

Mr. Nishinakamura’s wide range of business accomplishments with OPC includes instrumental participation in the launch of pharmaceutical products for the treatment of cardiovascular diseases. He also established OPC’s Ethics Committee as well as its global pharmacovigilance network, formulated a marketing strategy for Otsuka products in Japan, and played a leadership role in the applied development of Otsuka products in Japan using single nucleotide polymorphisms (SNPs).

\*\*\* MORE \*\*\*

## OMRI Names New Chairman and CEO Sept. 2, 2003

Mr. Nishinakamura holds a Bachelor of Science Degree, with a major in applied microbiological research in agricultural chemistry, from Kagoshima University, Japan, and has undertaken additional studies at Colorado State University. An avid horseback rider, Mr. Nishinakamura and his wife are relocating to the Rockville, Maryland area from Osaka, Japan.

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a diversified health care company guided by its philosophy: “Otsuka - people creating new products for better health worldwide” and dedicated to the research and development of innovative medical, pharmaceutical, and nutritional consumer products to improve the quality of human life. Otsuka has a diverse portfolio including central nervous system, cardiovascular, circulatory, gastro-intestinal, respiratory, dermatological, ophthalmologic, and anti-cancer therapies, and is pursuing research in genomics and protein function. The Otsuka Pharmaceutical Group is comprised of 51 businesses around the world and 22,000 employees, earning total revenues of \$4.3 billion annually.

Otsuka Maryland Research Institute, Inc. (OMRI) is involved in conducting all phases of clinical research and development of innovative healthcare products to address unmet medical needs. OMRI is well established in the scientific community as a globally focused organization that plays a leadership role in the research and development of Otsuka's ethical healthcare products. The Company is dedicated to the improvement of the quality of life and health of patients around the world. OMRI is part of the Otsuka Pharmaceutical Group.

# # #